A Viral Arms Race in the Body: Past, Current, and Future Coronaviruses
Finding Genius Podcast
Richard Jacobs
4.4 • 1K Ratings
🗓️ 23 October 2020
⏱️ 48 minutes
🧾️ Download transcript
Summary
As the cell employs its machinery to shut down the virus that's inside it, the virus makes proteins to shut down the cell's efforts. The scene is set, but how will this arms race end? The answer depends on many, many factors.
Listeners can tune in to explore the following:
- How to study the way in which obesity, diabetes, and host immunosuppressive states alter the trajectory of viral disease like that caused by SARS-CoV-2
- Whether it's possible to create drugs that can combat viruses that don't yet exist
- How SARS-CoV-2 enters cells, with a play-by-play look at what exactly is does prior, during, and after entry
- What evidence suggests that SARS-CoV-2 had been replicating in humans for a while—potentially months—before anyone knew about it
Since 2004, Matthew Frieman, PhD has been researching coronaviruses. In 2009, he established his own research lab at the University of Maryland School of Medicine, where he is an associate professor in the area of microbiology and immunology. First it was SARS-CoV, then MERS-CoV, and now SARS-CoV-2, the virus causing COVID-19. With each new coronavirus, he learns a little bit more about the tricks they use to enter and infect cells. He also learns more and more about therapeutics which could potentially combat the current virus and viruses to come.
A focal point of the research in Frieman's lab is on the role of comorbidity in disease progression, and how an understanding of this in lab mice might be reflected in humans. For instance, why do those with underlying conditions appear significantly more vulnerable to SARS-CoV-2, and more likely to suffer severe symptoms? His research is also focused on developing a broadly antiviral drug not only for SARS-CoV-2, but for viruses that emerge in the future.
The conversation covers the similarities and differences between SARS-CoV-1 and SARS-CoV-2, two primary entry methods of SARS-CoV-2, the role of the ACE2 receptor and TMPRSS2 protease, why more virions per cell means fewer ACE2 receptors, which means decreased capacity for lung tissue repair, how cells detect the presence of a virus and respond accordingly, characteristics of viral spread, structure, and function, virus-host interactions, research aimed at combining antibodies to create a dual antiviral effect against SARS-CoV-2, and so much more.
Visit https://www.medschool.umaryland.edu/profiles/Frieman-Matthew/ and follow Frieman on Twitter @MattFrieman.
Available on Apple Podcasts: apple.co/2Os0myK
Transcript
Click on a timestamp to play from that location
| 0:00.0 | Forget frequently asked questions common sense common knowledge or Google how about advice from a real genius |
| 0:06.8 | 95% of people in any profession are good enough to be qualified and licensed 5% go and beyond. They become very good at what they do. |
| 0:15.1 | But only 0.1% are real Jesus. |
| 0:18.3 | Richard Jacobs has made it his life's mission to find them for you. |
| 0:22.4 | He hunts down and interviews geniuses in every field, sleep science, cancer, stem cells, |
| 0:27.2 | ketogenic diets, and more. |
| 0:28.8 | Here come the geniuses. |
| 0:30.4 | This is the Finding Genius Podcast. |
| 0:33.0 | That is Richard Jacobs. |
| 0:35.0 | Hello, this is Richard Jacobs with the Finding Genius Podcast. |
| 0:41.0 | I have Matthew B. Freeman. He's an associate professor at |
| 0:44.4 | University of Maryland School of Medicine in the microbiology and |
| 0:48.8 | immunology area. And he has his own research which we'll get, and he's also here to participate in the virus book that I put it together. |
| 0:56.2 | So, Matt, thanks for coming. |
| 0:57.8 | Thanks for having me. |
| 0:58.8 | Happy to be here. |
| 0:59.8 | Yeah. |
| 1:00.8 | Well, if you would tell me about your research, what's that about first? |
| 1:02.8 | So my research is on coronavirus. |
| 1:05.2 | So we're taking this in the middle of a coronavirus pandemic, and it just so happens that I've |
| 1:10.0 | been working on coronavirus since around 2004 when I started my post-doc at the University of North Carolina in Jopla Hill. |
| 1:17.5 | And so there I started on SARS 1, which we now call it SARS 1, or generally called SARS, working on pathogenesis and |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Richard Jacobs, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Richard Jacobs and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.

